Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanqiu Song

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
American Journal of Translational Research|May 10, 2016
Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitroHui Feng, Ying Dong, Jing Wu, et al.
Frontiers in Molecular Biosciences|July 23, 2021
Novel Nanoliposomes Alleviate Contrast-Induced Nephropathy by Mediating Apoptosis Response in New Zealand RabbitsPeng Zhang, Xue Zhang, Jing Zhang, et al.
Carcinogenesis|January 1, 2019
Genetic variants in the calcium signaling pathway genes are associated with cutaneous melanoma-specific survivalXiaomeng Wang, Hongliang Liu, Yinghui Xu, et al.
Journal of Inflammation Research|April 3, 2023
Association of Neutrophil-to-Lymphocyte Ratio with Nutrition in Patients with Various Types of Malignant Tumors: A Multicenter Cross-Sectional StudyLihua Kang, Xiangliang Liu, Wei Ji, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2023
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)Jiayu Wang, Li Cai, Yanqiu Song, et al.
Acta Biomaterialia|July 25, 2025
Controlled Delivery of C-C Motif Chemokine Ligand 25 by a Hydrogel for Tumor Microenvironment Remodeling in Triple Negative Breast CancerMeng Guan, Junfeng Ding, Ge Zhu, et al.
Science Advances|February 18, 2020
Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9<sup>+</sup> T cellsHongmei Chen, Xiuxiu Cong, Chenxi Wu, et al.
JAMA Oncology|August 26, 2021
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical TrialYing Fan, Tao Sun, Zhimin Shao, et al.
Molecular Genetics & Genomic Medicine|April 11, 2019
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancerXiaozhen Wang, Haimeng Liu, Amina Maimaitiaili, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 23, 2016
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer]Binghe Xu, Fuguo Tian, Jingrui Yu, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
American Journal of Translational Research|May 10, 2016
Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitroHui Feng, Ying Dong, Jing Wu, et al.
Frontiers in Molecular Biosciences|July 23, 2021
Novel Nanoliposomes Alleviate Contrast-Induced Nephropathy by Mediating Apoptosis Response in New Zealand RabbitsPeng Zhang, Xue Zhang, Jing Zhang, et al.
Carcinogenesis|January 1, 2019
Genetic variants in the calcium signaling pathway genes are associated with cutaneous melanoma-specific survivalXiaomeng Wang, Hongliang Liu, Yinghui Xu, et al.
Journal of Inflammation Research|April 3, 2023
Association of Neutrophil-to-Lymphocyte Ratio with Nutrition in Patients with Various Types of Malignant Tumors: A Multicenter Cross-Sectional StudyLihua Kang, Xiangliang Liu, Wei Ji, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2023
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)Jiayu Wang, Li Cai, Yanqiu Song, et al.
Acta Biomaterialia|July 25, 2025
Controlled Delivery of C-C Motif Chemokine Ligand 25 by a Hydrogel for Tumor Microenvironment Remodeling in Triple Negative Breast CancerMeng Guan, Junfeng Ding, Ge Zhu, et al.
Science Advances|February 18, 2020
Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9<sup>+</sup> T cellsHongmei Chen, Xiuxiu Cong, Chenxi Wu, et al.
JAMA Oncology|August 26, 2021
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical TrialYing Fan, Tao Sun, Zhimin Shao, et al.
Molecular Genetics & Genomic Medicine|April 11, 2019
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancerXiaozhen Wang, Haimeng Liu, Amina Maimaitiaili, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 23, 2016
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer]Binghe Xu, Fuguo Tian, Jingrui Yu, et al.
Pageof 7